Diversified healthcare company CVS Health (NYSE:CVS) will be announcing earnings results tomorrow morning. Here’s what to expect.
CVS Health beat analysts’ revenue expectations by 0.8% last quarter, reporting revenues of $97.71 billion, up 4.2% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ same-store sales estimates and a solid beat of analysts’ EPS estimates.
Is CVS Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting CVS Health’s revenue to grow 5.4% year on year to $93.18 billion, improving from the 3.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.67 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CVS Health has missed Wall Street’s revenue estimates twice over the last two years.
Looking at CVS Health’s peers in the health insurance providers segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 15.4%, beating analysts’ expectations by 8.3%, and Elevance Health reported revenues up 14.8%, topping estimates by 5.3%. Centene traded down 3.3% following the results while Elevance Health was up 4.9%.
Read our full analysis of Centene’s results here and Elevance Health’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. CVS Health is down 4% during the same time and is heading into earnings with an average analyst price target of $76.13 (compared to the current share price of $65.26).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.